Sorafenib also inhibited polarized macrophage-induced Met activation in hepatocellular carcinoma cells (Figure 7), suggesting that sorafenib inhibited macrophage-induced EMT and migration of hepatocellular carcinoma cells via the HGF-Met signaling pathway. The gene discussed is MET; the disease is hepatocellular carcinoma.